The Pharmacogenetics of Optimal Warfarin Therapy in Chinese Patients After Heart Valve Replacement.

NCT02710747 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

500

Enrollment

OTHER

Sponsor class

Conditions

Heart Valve Disease
Older Than 18-years-old
Without Any Liver or Kidney Diseases

Interventions

GENETIC: CYP2C9;VKORC1

Sponsor

Guangdong Provincial People's Hospital